Upcoming Events

November 19, 2019 • 12:00 - 3:30 pm ET

Pieris Pharmaceuticals R&D Day

New York

Webcast

November 20, 2019

Jefferies 2019 London Healthcare Conference

London

December 3, 2019 • 10:35 am ET

Evercore ISI HealthCONx Conference 2019

Boston

Webcast

Past Events

November 11, 2019 • 8:00 am ET

Third Quarter 2019 Financial Results Conference Call

An archived replay of the call is available through December 11, 2019 and can be accessed by dialing 877-660-6853 (Toll Free US & Canada) or 201-612-7415 (International) and providing the Conference ID #13661472.

November 9, 2019 • 11:50 am ET

Society for Immunotherapy of Cancer (SITC) Annual Meeting

National Harbor, Maryland

October 1, 2019

2019 European Respiratory Society International Congress

September 9, 2019 • 9:10 am ET

H.C. Wainwright 21st Annual Global Investment Conference

Lotte New York Palace Hotel in New York City

Webcast

September 5, 2019 • 2:00 pm ET

Baird 2019 Global Healthcare Conference

InterContinental New York Barclay Hotel in New York City

Webcast

September 4, 2019

Citi 14th Annual Biotech Conference

Four Seasons Hotel in Boston

August 1, 2019 • 8:00 am ET

Second Quarter 2019 Financial Results Conference Call

July 31, 2019 • 8:00am ET

2019 Annual Meeting of Stockholders

Boston, MA

June 6, 2019 • 3:30 pm ET

Jefferies 2019 Healthcare Conference

New York, NY

Webcast

May 21, 2019 • 11:30 am ET

2019 RBC Capital Markets Global Healthcare Conference

New York, New York

Webcast

More past events »

Pieris Drug Pipeline

Pieris pipeline includes multiple fully proprietary as well as partnered programs in a number of different therapeutic areas. Our most advanced Anticalin program PRS-080 (hepcidin antagonist to treat anemia), our advanced respiratory program PRS-060 (1st-in-class inhaled IL4Ra antagonist to treat asthma) and several of our immuno-oncology (IO) multispecific programs (PRS-300 series), led by PRS-343 (a HER2/4-1BB bispecific), are examples of our fully proprietary programs. As we continue to build our IO and Respiratory franchises, we aim to ultimately develop Pieris into a fully-integrated pharmaceutical company by retaining commercial rights to several of these programs in major markets. For this purpose, we are also joining forces with other pharmaceutical companies, as exemplified by our strategic co-development IO alliance with Servier, with PRS-344 (a 4-1BB/PD-L1 bispecific) as the lead program of this collaboration, to which we retain full US rights.

For more information about our pipeline, click here.

Upcoming Events

Past Events

Q3 2019Quarterly Results

Q2 2019Quarterly Results

Q3 2019
Quarterly Results

Q2 2019
Quarterly Results